North America In-Vitro Diagnostics Market Analysis 2024-2030

Plastic Optic Fiber Market Report Thumbnail

North America In-Vitro Diagnostics Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others), and by End User (Stand Alone, Laboratory, Hospitals, Academics and Medical Schools, Point of Care Testing, and Other End Users) – Opportunity Analysis and Industry Forecast, 2024–2030

Download PDF

Speak to Our Analyst

Market Overview

The North America In-Vitro Diagnostics Market size was valued at USD 33.54 billion in 2023, and is predicted to reach USD 43.64 billion by 2030, at a CAGR of 3.4% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

IVD tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, these tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics. Also, immunoassay experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Rising Rates of Chronic and Infectious Diseases are Significantly Boosting the Market Growth in North America

The increasing prevalence of chronic and infectious diseases such as cancer, cardiovascular conditions, diabetes, and various infections is driving the demand for diagnostic tests in the global in-vitro diagnostics market. As healthcare systems work to tackle these rising health challenges, there is a stronger focus on early detection, disease monitoring, and personalized treatment strategies.

According to the World Health Organization, Noncommunicable Diseases (NCDs) account for a staggering 41 million deaths annually, representing around 74% of all global fatalities. Cardiovascular diseases are the leading cause, resulting in 17.9 million deaths each year, followed by cancers at 9.3 million, chronic respiratory diseases at 4.1 million, and diabetes at 2 million.

In-vitro diagnostics, with their ability to provide rapid and accurate diagnostic information, are indispensable in facilitating proactive healthcare interventions and improving patient outcomes. Consequently, the North America in-vitro diagnostics market is poised for substantial expansion as healthcare systems worldwide intensify efforts to combat the burgeoning burden of chronic and infectious diseases.

The Growing Aging Population Drives the Expansion of the In-Vitro Diagnostics Market in North America

The aging population, marked by a rising prevalence of age-related diseases and conditions worldwide, is a key driver for the growth of the market in the region. As people age, the incidence of these conditions increases, leading to a higher demand for diagnostic tests for early detection, monitoring, and management to prevent further progression and complications.

This demographic shift is clearly observable from the projected rise of individuals aged 65 years and older, expected to more than double from 761 million in 2021 to 1.6 billion by 2050 worldwide. As a result, healthcare providers are confronted with the increasing task of meeting the changing healthcare requirements of elderly individuals, driving the need for advanced diagnostic solutions.

Moreover, the specific healthcare demands of the aging population emphasize the necessity for precise diagnostic technologies tailored to individual needs. Therefore, the aging demographic plays a pivotal role in shaping the North America in-vitro diagnostics market demand and development, influencing its future trajectory.

High Research, Development, and Regulatory Approval Costs Hinder the IVD Market Growth in North America

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth in North America. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of growth in the North America IVD market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

U.S. Dominates the North America In-Vitro Diagnostics Market Share

The prevalence of chronic diseases serves as a significant growth driver for the IVD market in the U.S. Chronic conditions such as diabetes, cardiovascular diseases, and cancer are increasingly common among the population, leading to a heightened demand for diagnostic tests.

Early detection and ongoing monitoring of these diseases are crucial for effective management and treatment. The National association of Chronic Disease Directors reported that cardiovascular diseases accounts for one out of every three deaths in the U.S., totalling 859,000 deaths every year.

In response to this, the demand for molecular testings are rising, facilitating diagnosis, monitoring, and management of chronic diseases in this region. Through innovative technologies and advancements in diagnostic techniques, healthcare providers can better identify individuals at risk, tailor treatment plans to individual needs, and improve patient outcomes.

Canada to Witness Substantial Growth in the Market

Expansion in healthcare expenditure is significantly driving the in-vitro diagnostics industry growth in this region. The Canadian medical Association reported that, Canada allocates about USD 220 billion annually towards healthcare expenditure.

As healthcare expenditure increases, there is a greater allocation of resources towards improving healthcare infrastructure, enhancing medical facilities, and expanding access to healthcare services, including diagnostic testing. This includes the adoption of innovative products and platforms that offer more accurate, efficient, and timely diagnostic. These investments enable healthcare facilities to enhance their diagnostic capabilities, improve patient care, and achieve better treatment outcomes.

Competitive Landscape

The promising players operating in the North America in-vitro diagnostics market include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

North America In-Vitro Diagnostics Market Key Segments

By Type

Reagents
Instruments
Software & Services

By Technique

Immunodiagnostics
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Tests
- Chemiluminescence Immunoassay (CLIA)
- Enzyme-linked Immunosorbent spot (ELISpot)
- Radioimmunoassay (RIA)
- Western Blot
Hematology
Molecular Diagnostics
- PCR
- INAAT
- Hybridization
- DNA diagnostics
- Microarray
- Other Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
- Basic Metabolic Panel
- Liver Panel
- Renal Profile
- Lipid Profile
- Thyroid Function Panel
- Electrolyte Panel
- Speciality Chemicals
Other IVD Techniques

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others

By End User

Stand Alone Laboratory
Hospitals
Academics and Medical Schools
Point of Care Testing
Other End Users

By Country

U.S
Canada
Mexico

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 33.54 billion
Revenue Forecast in 2030	USD 43.64 billion
Value Growth Rate	CAGR of 3.4% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Rising Rates of Chronic and Infectious Diseases are Significantly Boosting the Market Growth. The Growing Aging Population Drives the Expansion of the In-Vitro Diagnostics Market.
Companies Profiled	10
Countries Covered	3
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

KEY PLAYERS

Roche Holding AG
Abbott Laboratories
Thermo Fisher Scientific Inc.
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.

1 INTRODUCTION

1.1 REPORT DESCRIPTION

1.2 RESEARCH METHODOLOGY

1.2.1 SECONDARY RESEARCH

1.2.2 DATA ANALYSIS FRAMEWORK

1.2.3 MARKET SIZE ESTIMATION

1.2.4 FORECASTING

1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET – EXECUTIVE SUMMARY

2.1. MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3 PORTER’S FIVE FORCE MODEL ANALYSIS

3.1 BARGAINING POWER OF SUPPLIERS

3.2 BARGAINING POWER OF BUYERS

3.3 DEGREE OF COMPETITION

3.4 THREAT OF SUBSTITUTE

3.5 THREAT OF NEW ENTRANTS

4 MARKET SHARE ANALYSIS

4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5 MARKET DYNAMICS

5.1 GROWTH DRIVERS

5.1.1 DRIVER 1

5.1.2 DRIVER 2

5.1.3 DRIVER 3

5.1.4 DRIVER 4

5.2 CHALLENGES

5.2.1 CHALLENGE 1

5.2.2 CHALLENGE 2

5.2.3 CHALLENGE 3

5.2.4 CHALLENGE 4

5.3 OPPORTUNITIES

5.3.1 OPPORTUNITY 1

5.3.2 OPPORTUNITY 2

6 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TYPE

6.1 OVERVIEW

6.2 REAGENTS

6.2.1 REAGENTS MARKET, BY COUNTRY

6.3 INSTRUMENTS

6.3.1 INSTRUMENTS MARKET, BY COUNTRY

6.4 SOFTWARE AND SERVICES

6.4.1 SOFTWARE AND SERVICES MARKET, BY COUNTRY

7 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNIQUE

7.1 OVERVIEW

7.2 IMMUNODIAGNOSTICS

7.2.1 IMMUNODIAGNOSTICS MARKET, BY TECHNIQUE

7.2.1.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) MARKET, BY COUNTRY

7.2.1.2 RAPID TESTS MARKET, BY COUNTRY

7.2.1.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) MARKET, BY COUNTRY

7.2.1.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT) MARKET, BY COUNTRY

7.2.1.5 RADIOIMMUNOASSAY (RIA) MARKET, BY COUNTRY

7.2.1.6 WESTERN BLOT MARKET, BY COUNTRY

7.2.2 IMMUNODIAGNOSTICS MARKET, BY COUNTRY

7.3 HEMATOLOGY

7.3.1 HEMATOLOGY MARKET, BY COUNTRY

7.4 MOLECULAR DIAGNOSTICS

7.4.1 MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

7.4.1.1 PCR MARKET, BY COUNTRY

7.4.1.2 INAAT MARKET, BY COUNTRY

7.4.1.3 HYBRIDIZATION MARKET, BY COUNTRY

7.4.1.4 DNA DIAGNOSTICS MARKET, BY COUNTRY

7.4.1.5 MICROARRAY MARKET, BY COUNTRY

7.4.1.6 OTHER MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

7.4.2 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

7.5 TISSUE DIAGNOSTICS

7.5.1 TISSUE DIAGNOSTICS MARKET, BY COUNTRY

7.6 CLINICAL CHEMISTRY

7.6.1 CLINICAL CHEMISTRY MARKET, BY TECHNIQUE

7.6.1.1 BASIC METABOLIC PANEL MARKET, BY COUNTRY

7.6.1.2 LIVER PANEL MARKET, BY COUNTRY

7.6.1.3 RENAL PROFILE MARKET, BY COUNTRY

7.6.1.4 LIPID PROFILE MARKET, BY COUNTRY

7.6.1.5 THYROID FUNCTION PANEL MARKET, BY COUNTRY

7.6.1.6 ELECTROLYTE PANEL MARKET, BY COUNTRY

7.6.1.7 SPECIALITY CHEMICALS MARKET, BY COUNTRY

7.6.2 CLINICAL CHEMISTRY MARKET, BY COUNTRY

7.7 OTHER IVD TECHNIQUES

7.7.1 OTHER IVD TECHNIQUES MARKET, BY COUNTRY

8 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION

8.1 OVERVIEW

8.2 INFECTIOUS DISEASES

8.2.1 INFECTIOUS DISEASES MARKET, BY COUNTRY

8.3 CANCER

8.3.1 CANCER MARKET, BY COUNTRY

8.4 CARDIAC DISEASES

8.4.1 CARDIAC DISEASES MARKET, BY COUNTRY

8.5 IMMUNE SYSTEM DISORDERS

8.5.1 IMMUNE SYSTEM DISORDERS MARKET, BY COUNTRY

8.6 NEPHROLOGICAL DISEASES

8.6.1 NEPHROLOGICAL DISEASES MARKET, BY COUNTRY

8.7 GASTROINTESTINAL DISEASES

8.7.1 GASTROINTESTINAL DISEASES MARKET, BY COUNTRY

8.8 OTHERS

8.8.1 OTHERS MARKET, BY COUNTRY

9 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END USER

9.1 OVERVIEW

9.2 STAND ALONE LABORATORY

9.2.1 STAND ALONE LABORATORY MARKET, BY COUNTRY

9.3 HOSPITALS

9.3.1 HOSPITALS MARKET, BY COUNTRY

9.4 ACADEMICS AND MEDICAL SCHOOLS

9.4.1 ACADEMICS AND MEDICAL SCHOOLS MARKET, BY COUNTRY

9.5 POINT OF CARE TESTING

9.5.1 POINT OF CARE TESTING MARKET, BY COUNTRY

9.6 OTHER END USERS

9.6.1 OTHER END USERS MARKET, BY COUNTRY

10 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY

10.1 OVERVIEW

10.2 UNITED STATES

10.2.1 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.2.2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.2.3 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.2.4 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.3 CANADA

10.3.1 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.3.2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.3.3 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.3.4 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER

10.4 MEXICO

10.4.1 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TYPE

10.4.2 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

10.4.3 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION

10.4.4 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET, BY END USER

11 COMPANY PROFILES

11.1 ROCHE HOLDING AG

11.1.1 COMPANY OVERVIEW

11.1.2 COMPANY SNAPSHOT

11.1.3 OPERATING BUSINESS SEGMENTS

11.1.4 PRODUCT PORTFOLIO

11.1.5 BUSINESS PERFORMANCE

11.1.6 BUSINESS SEGMENTS

11.1.7 GEOGRAPHIC SEGMENTS

11.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.1.9 PRIMARY MARKET COMPETITORS

11.2 ABBOTT LABORATORIES

11.2.1 COMPANY OVERVIEW

11.2.2 COMPANY SNAPSHOT

11.2.3 OPERATING BUSINESS SEGMENTS

11.2.4 PRODUCT PORTFOLIO

11.2.5 BUSINESS PERFORMANCE

11.2.6 BUSINESS SEGMENTS

11.2.7 GEOGRAPHIC SEGMENTS

11.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.2.9 PRIMARY MARKET COMPETITORS

11.3 THERMO FISHER SCIENTIFIC INC.

11.3.1 COMPANY OVERVIEW

11.3.2 COMPANY SNAPSHOT

11.3.3 OPERATING BUSINESS SEGMENTS

11.3.4 PRODUCT PORTFOLIO

11.3.5 BUSINESS PERFORMANCE

11.3.6 BUSINESS SEGMENTS

11.3.7 GEOGRAPHIC SEGMENTS

11.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.3.9 PRIMARY MARKET COMPETITORS

11.4 DANAHER CORPORATION

11.4.1 COMPANY OVERVIEW

11.4.2 COMPANY SNAPSHOT

11.4.3 OPERATING BUSINESS SEGMENTS

11.4.4 PRODUCT PORTFOLIO

11.4.5 BUSINESS PERFORMANCE

11.4.6 BUSINESS SEGMENTS

11.4.7 GEOGRAPHIC SEGMENTS

11.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.4.9 PRIMARY MARKET COMPETITORS

11.5 BECTON, DICKINSON AND COMPANY

11.5.1 COMPANY OVERVIEW

11.5.2 COMPANY SNAPSHOT

11.5.3 OPERATING BUSINESS SEGMENTS

11.5.4 PRODUCT PORTFOLIO

11.5.5 BUSINESS PERFORMANCE

11.5.6 BUSINESS SEGMENTS

11.5.7 GEOGRAPHIC SEGMENTS

11.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.5.9 PRIMARY MARKET COMPETITORS

11.6 SIEMENS HEALTHINEERS AG

11.6.1 COMPANY OVERVIEW

11.6.2 COMPANY SNAPSHOT

11.6.3 OPERATING BUSINESS SEGMENTS

11.6.4 PRODUCT PORTFOLIO

11.6.5 BUSINESS PERFORMANCE

11.6.6 BUSINESS SEGMENTS

11.6.7 GEOGRAPHIC SEGMENTS

11.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.6.9 PRIMARY MARKET COMPETITORS

11.7 BIOMÉRIEUX SA

11.7.1 COMPANY OVERVIEW

11.7.2 COMPANY SNAPSHOT

11.7.3 OPERATING BUSINESS SEGMENTS

11.7.4 PRODUCT PORTFOLIO

11.7.5 BUSINESS PERFORMANCE

11.7.6 BUSINESS SEGMENTS

11.7.7 GEOGRAPHIC SEGMENTS

11.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.7.9 PRIMARY MARKET COMPETITORS

11.8 SYSMEX CORPORATION

11.8.1 COMPANY OVERVIEW

11.8.2 COMPANY SNAPSHOT

11.8.3 OPERATING BUSINESS SEGMENTS

11.8.4 PRODUCT PORTFOLIO

11.8.5 BUSINESS PERFORMANCE

11.8.6 BUSINESS SEGMENTS

11.8.7 GEOGRAPHIC SEGMENTS

11.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.8.9 PRIMARY MARKET COMPETITORS

11.9 QIAGEN N.V.

11.9.1 COMPANY OVERVIEW

11.9.2 COMPANY SNAPSHOT

11.9.3 OPERATING BUSINESS SEGMENTS

11.9.4 PRODUCT PORTFOLIO

11.9.5 BUSINESS PERFORMANCE

11.9.6 BUSINESS SEGMENTS

11.9.7 GEOGRAPHIC SEGMENTS

11.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.9.9 PRIMARY MARKET COMPETITORS

11.10 BIO-RAD LABORATORIES, INC.

11.10.1 COMPANY OVERVIEW

11.10.2 COMPANY SNAPSHOT

11.10.3 OPERATING BUSINESS SEGMENTS

11.10.4 PRODUCT PORTFOLIO

11.10.5 BUSINESS PERFORMANCE

11.10.6 BUSINESS SEGMENTS

11.10.7 GEOGRAPHIC SEGMENTS

11.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT

11.10.9 PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 2. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 3. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 5. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 6. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 7. RAPID TESTS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 8. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 9. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 10. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 11. WESTERN BLOT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 12. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 13. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 14. PCR, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 15. INAAT, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 16. HYBRIDIZATION, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 17. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 18. MICROARRAY, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 19. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 20. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 21. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 22. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 23. LIVER PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 24. RENAL PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 25. LIPID PROFILE, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 26. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 27. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 28. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY 2023-2030, (MILLION USD)

TABLE 29. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 31. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 33. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 34. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 38. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 39. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 41. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 43. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 44. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 45. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

TABLE 46. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 47. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 48. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 49. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 50. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 51. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 52. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 53. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 54. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

TABLE 55. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

TABLE 56. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

TABLE 57. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

TABLE 58. ROCHE HOLDING AG: COMPANY SNAPSHOT

TABLE 59. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS

TABLE 60. ROCHE HOLDING AG: PRODUCT PORTFOLIO

TABLE 61. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 62. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 63. ROCHE HOLDING AG: KEY STRATERGY

TABLE 64. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 65. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS

TABLE 66. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 67. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 68. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 69. ABBOTT LABORATORIES: KEY STRATERGY

TABLE 70. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 71. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS

TABLE 72. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 73. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 74. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 75. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY

TABLE 76. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 77. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS

TABLE 78. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 79. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 80. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 81. DANAHER CORPORATION: KEY STRATERGY

TABLE 82. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

TABLE 83. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS

TABLE 84. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 85. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 86. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 87. BECTON, DICKINSON AND COMPANY: KEY STRATERGY

TABLE 88. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT

TABLE 89. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS

TABLE 90. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

TABLE 91. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 92. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 93. SIEMENS HEALTHINEERS AG: KEY STRATERGY

TABLE 94. BIOMéRIEUX SA: COMPANY SNAPSHOT

TABLE 95. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS

TABLE 96. BIOMéRIEUX SA: PRODUCT PORTFOLIO

TABLE 97. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 98. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 99. BIOMéRIEUX SA: KEY STRATERGY

TABLE 100. SYSMEX CORPORATION: COMPANY SNAPSHOT

TABLE 101. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS

TABLE 102. SYSMEX CORPORATION: PRODUCT PORTFOLIO

TABLE 103. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 104. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 105. SYSMEX CORPORATION: KEY STRATERGY

TABLE 106. QIAGEN N.V.: COMPANY SNAPSHOT

TABLE 107. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS

TABLE 108. QIAGEN N.V.: PRODUCT PORTFOLIO

TABLE 109. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 110. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 111. QIAGEN N.V.: KEY STRATERGY

TABLE 112. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

TABLE 113. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 114. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 115. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 116. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 117. BIO-RAD LABORATORIES, INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE, 2023-2030, (MILLION USD)

FIGURE 7. REAGENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 8. INSTRUMENTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 10. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2023-2030, (MILLION USD)

FIGURE 11. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 12. RAPID TESTS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 13. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 14. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 15. RADIOIMMUNOASSAY (RIA), MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 16. WESTERN BLOT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 17. IMMUNODIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 18. HEMATOLOGY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 19. PCR, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 20. INAAT, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 21. HYBRIDIZATION, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 22. DNA DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 23. MICROARRAY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 24. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 26. TISSUE DIAGNOSTICS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 27. BASIC METABOLIC PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 28. LIVER PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 29. RENAL PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 30. LIPID PROFILE, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 31. THYROID FUNCTION PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 32. ELECTROLYTE PANEL, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 33. SPECIALITY CHEMICALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 34. CLINICAL CHEMISTRY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 36. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2023-2030, (MILLION USD)

FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 38. CANCER, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 39. CARDIAC DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 43. OTHERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 44. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER, 2023-2030, (MILLION USD)

FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 46. HOSPITALS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 49. OTHER END USERS, MARKET VALUE, BY COUNTRY, 2023-2030, (MILLION USD)

FIGURE 50. NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY REGION 2023-2030, (MILLION USD)

FIGURE 51. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 52. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 53. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 54. UNITED STATES NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 55. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 56. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 57. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 58. CANADA NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 59. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TYPE 2023-2030, (MILLION USD)

FIGURE 60. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE 2023-2030, (MILLION USD)

FIGURE 61. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION 2023-2030, (MILLION USD)

FIGURE 62. MEXICO NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET VALUE, BY END USER 2023-2030, (MILLION USD)

FIGURE 63. ROCHE HOLDING AG: NET SALES, (2021-2023)

FIGURE 64. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS

FIGURE 65. ABBOTT LABORATORIES: NET SALES, (2021-2023)

FIGURE 66. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS

FIGURE 67. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2021-2023)

FIGURE 68. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS

FIGURE 69. DANAHER CORPORATION: NET SALES, (2021-2023)

FIGURE 70. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 71. BECTON, DICKINSON AND COMPANY: NET SALES, (2021-2023)

FIGURE 72. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 73. SIEMENS HEALTHINEERS AG: NET SALES, (2021-2023)

FIGURE 74. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS

FIGURE 75. BIOMéRIEUX SA: NET SALES, (2021-2023)

FIGURE 76. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS

FIGURE 77. SYSMEX CORPORATION: NET SALES, (2021-2023)

FIGURE 78. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 79. QIAGEN N.V.: NET SALES, (2021-2023)

FIGURE 80. QIAGEN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 81. BIO-RAD LABORATORIES, INC.: NET SALES, (2021-2023)

FIGURE 82. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

Frequently Asked Questions

The North America in-vitro diagnostics market size was valued at USD 33.54 billion in 2023 and is projected to grow at a CAGR of 3.4% to reach USD 43.64 billion by 2030.

The key market players operating in the North America in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

U.S. holds the largest share of the North America IVD market, owing to rising rates of chronic and infectious diseases.

High costs associated with research, development, and regulatory approval are significant factors restraining the North America in-vitro diagnostics market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the North America in-vitro diagnostics market landscape, in the coming future.

Download Free Sample

Yes, I have read the Privacy Policy

Multi User

$3,975

Single User

$2,975

Enterprise

$5,275

Datapack

$2,975

Our Clients

View All

Features
	Single User	Multi User	Enterprise User	Data Pack
	US $ 2,975	US $ 3,975	US $ 5,275	US $ 2,975
	1 user only	1 user only	Unlimited access within the Organization	1 user only

Free Customization	20 hours	40 hours	>60 hours	NA
Duration Of Free Analyst Support	3 months post purchase	6 months post purchase	12 months post purchase	NA
Direct Access to the Analyst Team Through Calls / Email
Deliverable Format
Deliverable Format
Discount on Your Next Purchase	No Discount	15%	No Discount	No Discount
Permission to Print the Report

Trending Report

North America In-Vitro Diagnostics Market

Market Overview

Rising Rates of Chronic and Infectious Diseases are Significantly Boosting the Market Growth in North America

The Growing Aging Population Drives the Expansion of the In-Vitro Diagnostics Market in North America

High Research, Development, and Regulatory Approval Costs Hinder the IVD Market Growth in North America

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

U.S. Dominates the North America In-Vitro Diagnostics Market Share

Canada to Witness Substantial Growth in the Market

Competitive Landscape

North America In-Vitro Diagnostics Market Key Segments

By Type

By Technique

By Application

By End User

By Country

KEY PLAYERS

Frequently Asked Questions

Download Free Sample

Our Clients

Features

Follow Us On

We Accept

Industries

Trending Report

North America In-Vitro Diagnostics Market

Market Overview

Rising Rates of Chronic and Infectious Diseases are Significantly Boosting the Market Growth in North America

The Growing Aging Population Drives the Expansion of the In-Vitro Diagnostics Market in North America

High Research, Development, and Regulatory Approval Costs Hinder the IVD Market Growth in North America

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

U.S. Dominates the North America In-Vitro Diagnostics Market Share

Canada to Witness Substantial Growth in the Market

Competitive Landscape

North America In-Vitro Diagnostics Market Key Segments

By Type

By Technique

By Application

By End User

By Country

KEY PLAYERS

Frequently Asked Questions

What is the size of the North America in-vitro diagnostics market?

Which are the key market players operating in the North America in-vitro diagnostics industry?

Which region holds the largest share of the North America IVD market?

What are the restraining factors in the in-vitro diagnostics market in North America?

What are the growth opportunities in the North America in-vitro diagnostics market landscape?

Download Free Sample

Our Clients

Related Report

Related Blogs

Technological Advancements Shaping The Minimally Invasive Surgical Systems Market

Revolutionizing Kidney Health: Latest Trends and Advancements in Dialysis Technology

Transforming Healthcare With Patient Monitoring Innovations